31st Annual PCF Scientific Retreat Poster Abstracts

31st Annual PCF Scientific Retreat Poster Abstracts
The Poster Session will be on October 24, 2024, 7:30 – 10:30 PM PT. There will not be a virtual PCF Retreat poster session component in 2024.
The poster abstract submission deadline has passed.
For questions about abstracts or posters, please email [email protected].

Poster Abstract Submission Guidelines

Author	Abstract Title
Abbas, Ahmed	Using Machine Learning to Predict RNA Pol II Interactions of Metastatic Prostate Cancer
Au, CheukMan Cherie	First-in Class AR V7/AR-fl Small Molecule Degrader for Prostate Cancer Therapeutics
Bevan, Charlotte	Detection of clinically informative circulating mRNA biomarkers for Prostate Cancer Prognosis Using an ISFET Lab-On-Chip Platform
Bhatia, Vipul	Engineering Next-Generation STEAP1 CAR T Cells: Development and Optimization for Enhanced Anti-Tumor Efficacy in Prostate Cancer
Brisbane, Wayne	Combining Prostate MRI and Micro-ultrasound to Omit Systematic Biopsy
Burnham, Leanne	Community-Based Prostate Screening for Black Men: Changing the Equity Landscape in Metropolitan Atlanta and Rural Georgia
Buteau, James	Radiation absorbed dose in patients with metastatic castration-resistance prostate cancer treated with [¹⁶¹Tb]Tb-PSMA-I&T
Cesano, Alessandra	Phase 1/2 Trial of Oral Masofaniten (EPI-7386) in Combination with Enzalutamide (Enz) Compared to Enz Alone in Metastatic Castration-Resistance Prostate Cancer (mCRPC) Subjects
Chakraborty, Goutam	Chromosome 13q deletion and lethal prostate cancer: Biomarker to cancer therapeutics
Chauhan, Pradeep	Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Cheng, Heather	Prostate screening for people with inherited risk of developing aggressive prostate cancer: The PATROL study
Chen, William	Investigating the Biological Basis of Multimodal AI Predictions in Prostate Cancer Using Spatial Single-cell Proteomics
Chen, William	Association between radiomic features and outcomes after metastasis-directed radiotherapy
Chesner, Lisa	Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer
Cole, Alexander	Use of Advanced Imaging Among United States Medicare Beneficiaries with Prostate Cancer
Cook, Leah	Characterization of patient (polymorphonuclear neutrophils) PMNs reveals a novel role for androgen receptor regulation of neutrophil immune response
Crawford, Taylor	Association of HOXB13 p.G84E with prostate cancer among 592,158 men
Daemen, Anneleen	ORIC-944, a potent and selective allosteric PRC2 inhibitor with best in-class properties demonstrates combination synergy with AR pathway inhibitors in prostate cancer models
De Sarkar, Navonil	Truncal Drivers as Key Determininant of Treatment Outcomes in Concurrent High TMB and HRD Metastatic Prostate Cancers
Ding, Chien-Kuang Cornelia	Application of Canary Histology Classifier in Prostate Biopsies for Risk Stratification
Ding, Chien-Kuang Cornelia	Artificial Intelligence-based Detection of Primary Small Cell Carcinoma of Prostate
Dornisch, Anna	Prostate cAncer integrated Risk Evaluation (P-CARE): a model to stratify risk of any, metastatic, and fatal prostate cancer
Doultsinos, Dimitrios	The activity of the Unfolded Protein Response Transducer IRE1 is a predictor of treatment resistant disease and a proxy of NEPC and RB1-loss like phenotypes
Edwards, Claire	Single-Cell Functional Biology in the Tumor-Bone Microenvironment: Identification of Individual Prostate Cancer Cells with High Metastatic Potential
El-Kenawi, Asmaa	ANPEP regulates one-carbon metabolism in prostate cancer
Eltit Guersetti, Felipe	Prostate Cancer Metastasis Disrupts Lacuna-Canalicular Network in Trabecular Bone
Feng, Weiran	Cell context dependency and vulnerabilities of ERG-driven prostate cancer
Flavell, Robert	CD46 targeted theranostics for imaging and treatment of prostate cancer
Fletcher, Claire	A Novel MicroRNA-Based Mechanism of DNA Damage in Prostate Cancer Requires Interaction with Topoisomerases and Basal Transcription Machinery
Fojo, Antonio	Comparable efficacy of abiraterone and enzalutamide in United States Veterans with metastatic castration-sensitive prostate cancer (mCSPC). An updated analysis.
Fonesca, Nicolette	Prediction of ctDNA fraction for genomic biomarker testing and implementation of ctDNA based prognostication in advanced prostate cancer
Garzotto, Mark	Phase II study of pembrolizumab plus androgen deprivation therapy in combination with radiotherapy for high-risk localized prostate cancer
Godolphin, Peter	Maximising patient benefit through enhanced evaluation of therapies and better characterisation of metastatic hormone-sensitive prostate cancer (mHSPC): STOPCAP M1 – past, present and future
Godolphin, Peter	Evaluating the evidence behind treatment recommendations in clinical guidelines for metastatic hormone-sensitive prostate cancer: A systematic review
Gong, Jun	A nationwide VA study on systemic treatment patterns in Black men with metastatic castration-resistant prostate cancer: Study update
Graff, Rebecca	Sociodemographics in relation to Satisfaction With Cancer Care, Social Support, Self-Efficacy, Barriers, and Change Strategies Among Individuals With Prostate Cancer
Grist, Emily	Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): an ancillary study of the STAMPEDE docetaxel trials
Grunberg, Nil	Bi-Directional Extracellular Vesicle-Mediated Communication Between Peri-Prostatic Adipose Tissue and Tumour Cells Drives Prostate Cancer Agressivity
Gueron, Geraldine	PKA signaling pathway as a key driver of SPP1/OPN expression in prostate cancer bone metastasis
Gurel, Bora	Integrative analyses of patterns of CD3 T-cell distribution in metastatic hormone-sensitive castration-resistance prostate cancer
Haas, Roni	Divergent Evolution in Bilateral Prostate Cancer: a Case Study
Hahn, Andrew	Body composition and the efficacy of pre-operative hormone therapy (HT) for men with localized and/or locally advanced prostate cancer
Halabi, Susan	A New Prognostic Model of Overall Survival (OS) in patients (pts) with Metastatic Hormone Sensitive Prostate cancer (mHSPC)
He, Househeng Hansen	Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation
Hong, Julian	Development of a machine learning model to predict overall survival results from randomized clinical trials of patients with metastatic prostate cancer
Hossain, Md Niamat	The αVβ3 integrin/NgR2 complex is upregulated in NEPrCa and is a novel therapeutic target
Hsiung, Chris	Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations
Hsu, Sarah	Identification of Asporin as a HER3 ligand exposes a therapeutic vulnerability in metastatic prostate cancer
Hurley, Paula	Automated AI Tumor Burden Analysis in PSMA & FDG PET and Lu-177 PSMA Quantitative SPECT with Global Threshold Regional Consensus Network (GTRC-Net)
Jackson, Price	Automated AI Tumor Burden Analysis in PSMA & FDG PET and Lu-177 PSMA Quantitative SPECT with Global Threshold Regional Consensus Network (GTRC-Net)
Jaiswal, Praveen	Digital spatial profiling of ore-and post-treatment GR+ metastatic CRPC from a phase I trial of enzalutamide and a GR antagonist reveals cAMP and MAPK gene expression pathway suppression after treatment
Jamaspishvili, Tamara	A Single-center Retrospective Observational Study of Current Management Practices of Localized High/Very-High-Risk and Advanced Hormone Sensitive Prostate Cancer Patients
James, Nicholas	The Man Van – Using Mobile Targeted Case-Finding to Address Health Inequalities in Prostate Cancer
Jamieson, Christina	Analysis of Wnt5A/ROR1 Signaling Inhibition as Cancer Stem Sell Targeting Therapy for Metastatic Prostate Cancer Using Live Organoid Time Lapse Microscope Imaging
Jatwani, Karan	Risk Assessment of Myelosuppression with PARP Inhibitors in Prostate Cancer: Insights from FAERS
Jeyapalan, Jennie	Genomic determinants of prostate cancer in Zambian patients
Jeyapalan, Jennie	ASH1L methyltransferase: a therapeutic target in prostate cancer?
Jeyapalan, Jennie	Epitranscriptomic determinants of enzalutamide resistance
Kamran, Sophia	Integrative Profiling of Tumor-Immune Dynamics and Evolution in Response to Radiotherapy for Oligometastatic Prostate Cancer
Kanadia, Rahul	Leveraging minor intron classification to target their splicing to treat prostate cancer
Kanayama, Mayuko	Clinical and functional characterization of the HOXB13 X285K germline mutation specific to men of African-ancestry
Kenfield, Stacey	SELF-EFFICACY IS ASSOCIATED WITH HIGHER DIET QUALITY AMONG MEN WITH PROSTATE CANCER
Ketola, Kirsi	Secreted factors from M1 macrophages drive prostate cancer stem cells plasticity by upregulating NANOG SOX2, and CD44 through NFxB- signaling
Knudsen, Beatrice	Predicting Metastatic Risk at Diagnosis from Digital Pathology Slides in the VA Health Care System
Kotula, Leszek	Defining ABI1-driven mechanism of ezalutamide resistance.
Kregel, Steven	Clinically relevant humanized mouse models of metastatic prostate cancer facilitate therapeutic evaluation
Ku, Anson	Club-like cells and PIGR expression are associated with inflammatory high-risk, localized prostate cancer
Kumar, Rajendra	CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor
Kwan, Edmond	Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabaitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)
Labanca, Estefania	From Tumor Suppression to Bone Remodeling: The Dual Role of Ra-233 in Advanced Prostate Cancer
Labbé, David	FOXA1 control of MYC-driven metabolic adaptation in aggressive prostate cancer
Lallous, Nada	Investigating the distinct phase separation properties of androgen receptor isoforms in prostate cancer
Leiter, Amanda	Impact of diabetes on cardiovascular outcomes in prostate cancer survivors receiving androgen deprivation therapy
Li, Chennan	Harnessing the ower of liquid biopsy for understanding mechanisms of PD-L1/PARP1-targeted therapy resistance in metastatic castration-resistance prostate cancer
Li, Haolong	Developing novel PTGES3 inhibitors as next generation agents for mCRPC
Li, Yun	Metabolic Modulation of Androgen-Receptor Signaling Inhibitor Mediated Radiosensitization
Lorenzin, Francesca	ERG induces persistent inflammatory and senescence-associated responses in prostate cancer
Luo, Jie	Oncogenic enhanceosomes are disabled by p300/CBP degradation
Lynch, Julie	Incorporating Structured and Unstructured Data Sources to Identify Hereditary Cancer Testing among Veterans with Metastatic Castration-Resistance Prostate Cancer
Lyu, Aram	Identification and therapeutic target of myleoid-mediated mechanisms of immunotherapy resistance in prostate cancer
Madan, Ravi	A Clinical Trial Combining a Tumor Targeting Immunocytokine (PDS01ADC) and Enzalutamide without Testosterone Lowering Therapy in Biochemically Recurrent Prostate Cancer
Mao, Zhiyuan	Tuning TCR Immunotherapy Targeting Prostatic Acid Phosphatase via Catchbond Modifications for Advanced Prostate Cancer
Marshall, Catherine	Bipolar androgen therapy (BAT) and dynamics of clonal hematopoiesis
Mavingire, Nicole	Investigating the Proteomes and Metabolomes of HER2-positive Prostate Cancer in Response to Trastuzumab Therapy
Maynard, Janielle	Androgen Receptor- Mediated Regulation of the Prostate Tumor Microenvironment in Black Men
Mei, Shenglin	Single cell and spatial transcriptomics reveal tumor associated macrophages mediate prostate cancer progression and metastasis.
Millan, David	AUTX703, a Highly Potent and selective KAT2A and KAT2B Protein Degrader, Induces Cell State Changes and Inhibits Growth in NEPC and SCLC cancers
Morel, Katherine	Dimethylaminoparthenolide augments the radiation response in prostate cancer
Morris, Michael	Efficacy of [¹⁷⁷Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)
Murad, John	Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery against prostate cancer
Nelson, Colleen	Evexomostat/SDX-7320 demonstrates potent anti-tumor effects across stages of prostate cancer progression, including treatment refractory and neuroendocrine (AAVPC) phenotypes
Nickols, Nicholas	Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases
Nouruzi, Shaghayegh	ASCL1-DRIVEN EPIGENETIC AND METABOLOMICS PROGRAMS IN NEUROENDOCRINE PROSTATE CANCER
Pandey, Apurva	Conditionally activated membrane binding probes for improved targeted radiotherapy in metastatic castration resistant prostate cancer.
Papachristodoulou, Alexandros	Aging-associated molecular drivers of mitochondrial dysfunction accelerate prostate carcinogenesis
Patel, Krishnan	AIRSTREAM:Artificial Intelligence (AI)-Based Lesion Kinetics Apraisal for the Selection of Therapeutic Targets for Focal Stereotactic Body Radiation Therapy (SBRT) in Patients with Oligoprogessive Metastatic Castration Resistance (mCRPC)
Patton, Robert	A deep learning framework for predicting gene expression from cell-free DNA
Plymate, Stephen	Increased glycolytic activity in the hypoxic environment is enhanced by P53/RB1 loss
Quigley, David	Convergent. evolution of complex structural variants drives therapy resistance in metastatic prostate cancer
Rajendran, Rithika	Response of HER2-expressing Prostate Cancer to Trastuzumab Deruxtecan
Rajendran, Rithika	The Association and Significance of HER2 and HER3 positivity in Prostate Adenocarcinoma
Ravi, Praful	Prognostic impact of residual cancer burden (RCB) on long-term outcomes after neoadjuvant (neo) androgen receptor pathway inhibitor (ARPI) and radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC): a pooled analysis of phase 2 trials
Rhie, Suhn	DNA methylation signatures linked to different grades of prostate tumors from African American and European American patients
Rojo, Domingo Mariluz	Restriction Spectrum Imagining as a quantitative biomarker for prostate cancer with reliable positive predictive value
Sachdeva, Ashwin	Fracture-related hospitalisations in de novo advanced or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE abiraterone acetate plus prednisone + / – enzalutamide and M1 \| RT phase 3 trials using health systems data
Sachdeva, Ashwin	Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE
Sachdeva, Ashwin	A randomised phase 3 evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (0) prostate cancer; efficacy results from the PATCH and STAMPEDE trials.
Salari, Keyan	Risk-adapted screening with multiparametric MRI for individuals at high risk of prostate cancer in the PROGRESS study
Salji,Mark	Prostate Specific Membrane Antigen (PSMA) related Neuronal Metabolites in Treatment Resistant Prostate Cancer
Sanchez, Leslie	Clinical Trials for Prostate Cancer Patients in the VA Medical System
Sanin, David	Myleoid Cell Regulation in Patients with Advanced Prostate Cancer treated with Bipolar Androgen Therapy
Schafer, Cara	Immune profiling or prostate tumors from a military cohort of African American and Caucasian American patients
Schmidt, Daniel	Targeting Pyruvate Kinase to Induce Metabolic Dependencies in Prostate Cancer
Shoen, Martin	Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone sensitive prostate cancer (mHSPC) by volume of disease
Schweizer, Michael	Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC)
Scurll, Josh	The landscape of genomic alterations and their phenotype association in high-risk localized prostate cancer in the Genomic Umbrella Neoadjuvant Study
Semenova, Galina	Targeting Advanced Prostate Cancer with Antibody-Drug Conjugate (ADC) Combinations
Sena, Laura	Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer
Sentana Lledo, Daniel	Genetic Drivers of Quality Of Life in Prostate Cancer – An Evaluation of Genetic Polymorphisms, atient Reported outcomes, and Adverse Events in E3805 CHAARTED trial
Shakhnazaryan, Nana	Exploring Social Vulnerability in Prostate Cancer management: Insights from Watchful Waiting and Active Surveillance (1998-2017)
Shakhnazaryan, Nonna	Impact of Socioeconomic Status and Community Vulnerability on Treatment Slection and Outcomes in Intermediate and High-Risk Prostate Cancer: A Pathway to Reducing Disparities
Sharifi, Marina	High purity CTC RNA sequencing identifies poor prognosis lineage states in castrate resistant prostate cancer
Shibata, Maho	Macrophages of multiple hematopoietic origins reside in the developing prostate
Shobaki, Nour	Establishing a Preclinical Model to Predict and Mitigate CAR T Cell Toxicity in Prostate Cancer
Shrestha, Raunak	An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression
Siddiqui, Bilal	A pilot presurgical trial of REGN5678 (Anti-PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy
Sim, Woogwang	PTEN/P53 Altered Prostate Cancer Has Unique Role for Tumor-Associated Macrophage Upon Androgen Signaling Inhibitor Resistance
Sjöström, Martin	5hmC-sequencing of matched cfDNA and tissue from men with mCRPC is concordant and identifies loss of AR signaling in NEPC and DNPC
Skog, Johan	Integrative multi-omic analysis of extracellular vesicle transcriptomics profiling combined with cfDNA methylation reveals improved stratification of low-risk and high-risk prostate cancer patients in urine-based liquid biopsy.
Soh, Pamela	Role of the Y-chromosome in the ethnic disparities and prostate cancer presentation
Sokolova, Alexandra	Concurrent Chemo-Hormonal Therapy of Enzalutamide (ENZ) and Cabazitaxel (CAB) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Final Analysis of Objective Response Rate (ORR), Radiographic Progression-Free Survival (rPFS), and Overall Survival (OS)
Sridaran, Dhivya	Targeting CK-1-SHP2 signaling using (R)-9b: Phase I clinical trial for prostate cancer
Sumiyoshi, Takayuki	Establishment of a novel transcriptome analysis for metastatic castration-sensitive prostate cancer using long-read sequencing technologies
Sun, Yue	Nonlinear Microscopy Provides Non-destructive Rapid Pathology Annotations for High-quality Prostatic Tissue Procurement and Translational Research
Szempruch, Tony	Discovery of a completely novel class of androgen-competitive AR inhibitors that can combat drug resistance due to AR gene amplification
Tabrizian, Nakisa	Receptor Tyrosine Kinase ROR2 as a Candidate for Antibody-Drug Conjugates in Androgen Receptor-Independent Prostate Cancer
Takeda, David	Profiling the Prostate Cancer Epigenome Using Circulating Nucleosomes in Plasma
Taylor, Amy	Fragmentomics of cell free DNA from targeted panels in genitourinary malignancies
Tendler, Salomon	A Theranostic Approach: Therapy of Delta-Like Ligand 3 Expressing Neuroendocrine Prostate Cancer
Traphagen, Nicole	Defining the effects of PARP inhibition on androgen receptor function in homologous recombination- proficient prostate cancer
Trigos Gomez, Anna	Neuroendocrine, amphicrine and AR ⁺ disease across lesions in a single mCRPC patient reveals a link between plasticity and clonal evolution
Vazquez, Elba	Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven 7-Gene Stemness Signature that Predicts Progression
Venkadakrishnan, Varadha Balaji	EZh2-mediated epigenetic underpinnings in advanced prostate cancer subtypes
Wei, Xiao	Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with ¹⁷⁷Lu-PSMA-617 versus change of ARPI in PSMAfore
Weiner, Adam	Molecular hallmarks of prostate-specific membrane antigen in treatment-naive prostate cancer
Wen, Ru	Targeting Siglec-9 immune checkpoint with CD59 as a potential ligand to inhibit prostate cancer progression
Wen, Ru	FXYD5 plays diverse roles in immune evasion and tumor progression in prostate cancer
Wurzer, Alexander	Targeted alpha-therapy with ²²⁵Ac-labeled PSMA ligands: A preclinical investigation the fate of the decay nuclides
Wyatt, Alex	DECIDE Survey (Decision-making, Experience, and Confidence In Determining Genomic Evaluation) – Updated Results by the PRECISION Registry Study Team
Xin, Li	Suppressing FZD6 attenuates DNA double-strand break repair and sensitizes advanced prostate cancers to genotoxic agents
Xu, Xin	The Transcriptional and Functional Landscape of N⁶-Methyladenosine in Localized Primary Prostate Cancer
Younger, Noah	Identification and characterization of PLUTO-201, a novel IncRNA associated with prostate cancer metastasis
Yu, Evan	Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab plus carboplatin/etoposide or carboplatin/etoposide alone for patients with metastatic neuroendocrine prostate cancer
Yu, Evan	Phase 1b/2 KEYNOTE-365 cohort J: Pembrolizumab plus belzutifan or belzutifan monotherapy in patients with docetaxel-treated metastatic castration-resistant prostate cancer
Yuan, Wei	Androgen Receptor Blockade in Prostate Cancer Drives Tumour-Fuelling Inflammation Through STING
Zhao, Di	CHD1 Loss Hijacks SREBP2-mediated Cholesterol Biosynthesis to Fuel SPOP-deficient Prostate Cancer and Confers Resistance to Castration
Zhu, Xiaolin	Investigating SSTR1 as an Actionable Drug Target in Prostate Cancer Resistant to Androgen Receptor Signaling Inhibitors
Zorko, Nicholas	Redirecting Natural Killer Cells to Target B7-H3 Using Tri-specific Killer Engagers or Secreted Camelid Nanobody Engagers and Chimeric Antigen Receptors

https://www.pcf.org/scientific-retreat/31st-annual/poster-abstracts/